Non-Hodgkin Lymphoma, B-cell
Oncology·MeSH: Lymphoma, B-Cell
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| hem101 | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for Non-Hodgkin Lymphoma, B-cell?
BioSniper tracks 1 drug in development for Non-Hodgkin Lymphoma, B-cell across 1 company.
How many clinical trials target Non-Hodgkin Lymphoma, B-cell?
There are 1 clinical trial targeting Non-Hodgkin Lymphoma, B-cell tracked by BioSniper.
What is the prevalence of Non-Hodgkin Lymphoma, B-cell?
The estimated prevalence of Non-Hodgkin Lymphoma, B-cell is approximately 30.0 per 100,000 population.
Deep-dive into Non-Hodgkin Lymphoma, B-cell
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis